NCT04201457 - A Trial of Dabrafenib, Trametinib and Hydroxychloroquine for Patients With Recurrent LGG or HGG With a BRAF Aberration | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 17, 2020

Primary Completion Date

March 31, 2027

Study Completion Date

June 30, 2030

Conditions

Low Grade Glioma (LGG) of Brain With BRAF AberrationHigh Grade Glioma (HGG) of the Brain With BRAF AberrationLow Grade Glioma of Brain With Neurofibromatosis Type 1

Interventions

DRUG

Dabrafenib

Dabrafenib capsule; Dabrafenib Dispersible Tablet

DRUG

Trametinib

Tablet; Powder for Oral Solution

DRUG

Hydroxychloroquine

Tablet

Trial Locations (15)

10065

Memorial Sloan Kettering Cancer Center, New York

15224

Children's Hospital of Pittsburgh, Pittsburgh

20892

National Cancer Institute Pediatric Oncology Branch, Bethesda

30322

Children's Healthcare of Atlanta, Atlanta

32608

University of Florida, Gainesville

38105

St. Jude Children Research Hospital, Memphis

43205

Nationwide Children's Hospital, Columbus

45229

Cincinnati Children Hospital Medical Center, Cincinnati

60614

Lurie Children's Hospital-Chicago, Chicago

77030

Texas Children's Cancer Center, Houston

80045

Children's Hospital Colorado, Aurora

85016

Phoenix Children's Hospital, Phoenix

90026

Children's Hospital Los Angeles, Los Angeles

94304

Lucile Packard Children's Hospital at Stanford University Medical Center, Palo Alto

20010-2970

Children's National Medical Center, Washington D.C.

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

collaborator

American Lebanese Syrian Associated Charities

OTHER

lead

Pediatric Brain Tumor Consortium

NETWORK